$PCVX
Vaxcyte, Inc.

2021 Q1 Form 10-K Financial Statement

#000156459021016110 Filed on March 29, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.890M $4.790M $3.050M
YoY Change 79.57% 34.96%
% of Gross Profit
Research & Development $17.26M $14.66M $18.18M
YoY Change -29.02% 9.57% 82.36%
% of Gross Profit
Depreciation & Amortization $347.0K $340.0K $360.0K
YoY Change -9.64% -46.03% 16.13%
% of Gross Profit
Operating Expenses $23.14M $19.45M $21.22M
YoY Change -16.14% 22.83% 73.51%
Operating Profit -$23.14M -$19.45M -$21.22M
YoY Change -16.14% 22.83% 73.51%
Interest Expense $1.920M -$1.610M -$130.0K
YoY Change 27328.57% -1281.82%
% of Operating Profit
Other Income/Expense, Net $1.923M -$1.284M $904.0K
YoY Change 323.57% -205.59% -42.31%
Pretax Income -$21.22M -$20.74M -$20.32M
YoY Change -21.81% 90.44%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$21.22M -$20.74M -$20.32M
YoY Change -21.82% 41.83% 90.53%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$414.7K -$405.7K -$1.722M
COMMON SHARES
Basic Shares Outstanding 51.33M 50.95M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q4 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $321.1M $386.2M $410.0M
YoY Change 107.43%
Cash & Equivalents $199.8M $386.2M $410.0M
Short-Term Investments $122.2M
Other Short-Term Assets $3.600M $2.800M $3.000M
YoY Change -5.26%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $324.7M $389.0M $413.1M
YoY Change 104.73% 530.24%
LONG-TERM ASSETS
Property, Plant & Equipment $4.994M $3.272M $2.800M
YoY Change 51.33% -3.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $49.80M
YoY Change
Other Assets $1.900M $550.0K $400.0K
YoY Change 216.67% -5.82%
Total Long-Term Assets $57.70M $3.822M $3.100M
YoY Change 1379.49% -3.85%
TOTAL ASSETS
Total Short-Term Assets $324.7M $389.0M $413.1M
Total Long-Term Assets $57.70M $3.822M $3.100M
Total Assets $382.4M $392.8M $416.2M
YoY Change 135.32% 497.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $31.90M $29.79M $2.600M
YoY Change 1081.48% 782.26%
Accrued Expenses $5.774M $3.766M $30.30M
YoY Change -73.63% 188.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $55.00M $46.86M $32.90M
YoY Change 124.49% 324.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $400.0K $112.0K $100.0K
YoY Change 100.0% -53.72%
Total Long-Term Liabilities $400.0K $112.0K $100.0K
YoY Change -50.0% -53.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $55.00M $46.86M $32.90M
Total Long-Term Liabilities $400.0K $112.0K $100.0K
Total Liabilities $55.40M $46.98M $33.00M
YoY Change 118.97% 299.48%
SHAREHOLDERS EQUITY
Retained Earnings -$198.6M -$156.8M
YoY Change 81.59%
Common Stock $544.4M $540.0M
YoY Change 18205.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $326.9M $345.8M $383.2M
YoY Change
Total Liabilities & Shareholders Equity $382.4M $392.8M $416.2M
YoY Change 135.32% 497.93%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2020 Q2
OPERATING ACTIVITIES
Net Income -$21.22M -$20.74M -$20.32M
YoY Change -21.82% 41.83% 90.53%
Depreciation, Depletion And Amortization $347.0K $340.0K $360.0K
YoY Change -9.64% -46.03% 16.13%
Cash From Operating Activities -$13.21M -$10.77M -$9.180M
YoY Change -3.14% -54.88% -32.05%
INVESTING ACTIVITIES
Capital Expenditures $1.246M -$730.0K -$50.00K
YoY Change 257.02% -28.43% -68.75%
Acquisitions
YoY Change
Other Investing Activities -$172.2M $0.00
YoY Change
Cash From Investing Activities -$173.4M -$730.0K -$50.00K
YoY Change 49582.23% -28.43% -68.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 487.0K 550.0K 264.5M
YoY Change -99.56% -98.68% -377928.57%
NET CHANGE
Cash From Operating Activities -13.21M -10.77M -9.180M
Cash From Investing Activities -173.4M -730.0K -50.00K
Cash From Financing Activities 487.0K 550.0K 264.5M
Net Change In Cash -186.4M -10.95M 255.2M
YoY Change -294.53% -165.06% -1957.71%
FREE CASH FLOW
Cash From Operating Activities -$13.21M -$10.77M -$9.180M
Capital Expenditures $1.246M -$730.0K -$50.00K
Free Cash Flow -$14.45M -$10.04M -$9.130M
YoY Change 3.35% -56.06% -31.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
414000
CY2019Q4 pcvx Accrued Manufacturing Expenses
AccruedManufacturingExpenses
5777000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001649094
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.593
CY2020Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
20390095
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.003
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.784
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.770
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.782
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.014
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-39323
CY2020 dei Entity Registrant Name
EntityRegistrantName
VAXCYTE, INC.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4233385
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
353 Hatch Drive
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Foster City
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94404
CY2020 dei City Area Code
CityAreaCode
650
CY2020 dei Local Phone Number
LocalPhoneNumber
837-0111
CY2020 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2020 dei Trading Symbol
TradingSymbol
PCVX
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
949500000
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
51327638
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
386200000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58976000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2804000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
550000
CY2019Q4 us-gaap Assets
Assets
65698000
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.026
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.812
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.941
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.804
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.024
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.029
CY2019Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
19000
CY2020Q4 us-gaap Liabilities
Liabilities
46983000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
161000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
46861000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11052000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
10000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
112000
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-12000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2747000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
389004000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
61723000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3272000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3391000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
584000
CY2020Q4 us-gaap Assets
Assets
392826000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
29785000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3376000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
284000
CY2020Q4 pcvx Accrued Manufacturing Expenses
AccruedManufacturingExpenses
13012000
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
677000
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
15000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3766000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1305000
CY2020Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
14000
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
17000
CY2019Q4 pcvx Redeemable Convertible Preferred Stock Warrant Liability
RedeemableConvertiblePreferredStockWarrantLiability
450000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
242000
CY2019Q4 us-gaap Liabilities
Liabilities
11761000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
52000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51071593
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51071593
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4059909
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4059909
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
54000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
544353000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2967000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-198564000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109347000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
345843000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-106373000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
392826000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
65698000
CY2020 pcvx Research And Development Expense To Related Party
ResearchAndDevelopmentExpenseToRelatedParty
1331000
CY2019 pcvx Research And Development Expense To Related Party
ResearchAndDevelopmentExpenseToRelatedParty
1137000
CY2018 pcvx Research And Development Expense To Related Party
ResearchAndDevelopmentExpenseToRelatedParty
1878000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
73564000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45607000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30145000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16017000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8546000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-135000
CY2018 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
42000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6048000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5388000
CY2020 us-gaap Operating Expenses
OperatingExpenses
89581000
CY2019 us-gaap Operating Expenses
OperatingExpenses
54153000
CY2018 us-gaap Operating Expenses
OperatingExpenses
35533000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-54153000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-35533000
CY2019 us-gaap Interest Expense
InterestExpense
40000
CY2018 us-gaap Interest Expense
InterestExpense
75000
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
903000
CY2020 pcvx Grant Income
GrantIncome
2478000
CY2019 pcvx Grant Income
GrantIncome
237000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2351000
CY2019 pcvx Change In Fair Value Of Redeemable Convertible Preferred Stock
ChangeInFairValueOfRedeemableConvertiblePreferredStock
3185000
CY2018 pcvx Change In Fair Value Of Redeemable Convertible Preferred Stock
ChangeInFairValueOfRedeemableConvertiblePreferredStock
5178000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
364000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3879000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-89217000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-50274000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-29485000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.02
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-13.25
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.12
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29545810
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3795090
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3629896
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-29130000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2018 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
133000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-57728000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
322000
CY2019 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
122000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1185000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-50274000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-106373000
CY2020 pcvx Temporary Equity Conversion Of Preferred Stock Value
TemporaryEquityConversionOfPreferredStockValue
270190000
CY2020 pcvx Adjustments To Additional Paid In Capital Warrant Liability Write Off
AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff
629000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
264007000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
635000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
374000
CY2020 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
164000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5434000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-89217000
CY2020 us-gaap Profit Loss
ProfitLoss
-89217000
CY2020 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-34000
CY2019 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-1000
CY2018 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-54000
CY2020 us-gaap Asset Impairment Charges
AssetImpairmentCharges
267000
CY2019 us-gaap Profit Loss
ProfitLoss
-50274000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1405000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
749000
CY2018 pcvx Expense On Issuance Of Redeemable Convertible Preferred Stock Warrant
ExpenseOnIssuanceOfRedeemableConvertiblePreferredStockWarrant
465000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
179000
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3000
CY2019 pcvx Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liabilities
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities
3185000
CY2018 pcvx Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liabilities
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities
5178000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
58000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1070000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
378000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
75000
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-120000
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
412000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
26102000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
868000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1266000
CY2020 pcvx Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-130000
CY2019 pcvx Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-775000
CY2018 pcvx Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
541000
CY2020 pcvx Increase Decrease In Accrued Manufacturing Expenses
IncreaseDecreaseInAccruedManufacturingExpenses
7235000
CY2019 pcvx Increase Decrease In Accrued Manufacturing Expenses
IncreaseDecreaseInAccruedManufacturingExpenses
3970000
CY2018 pcvx Increase Decrease In Accrued Manufacturing Expenses
IncreaseDecreaseInAccruedManufacturingExpenses
1646000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2207000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
718000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
73000
CY2018 pcvx Increase Decrease In Accrued Legal Settlement
IncreaseDecreaseInAccruedLegalSettlement
-850000
CY2020 pcvx Increase Decrease In Deferred Rent And Other Long Term Liabilities
IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities
-11000
CY2019 pcvx Increase Decrease In Deferred Rent And Other Long Term Liabilities
IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities
77000
CY2018 pcvx Increase Decrease In Deferred Rent And Other Long Term Liabilities
IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities
9000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46628000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47145000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30466000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1155000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1195000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1774000
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
50000
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1105000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1195000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1773000
CY2020 pcvx Payments Of Capital Lease Obligations
PaymentsOfCapitalLeaseObligations
61000
CY2019 pcvx Payments Of Capital Lease Obligations
PaymentsOfCapitalLeaseObligations
278000
CY2018 pcvx Payments Of Capital Lease Obligations
PaymentsOfCapitalLeaseObligations
283000
CY2020 pcvx Proceeds From Initial Public Offering Net Of Underwriters Commissions And Discounts
ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts
267375000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3368000
CY2020 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
109879000
CY2019 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
42500000
CY2018 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
62345000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
635000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
322000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
CY2020 pcvx Proceeds From Issuance Of Common Stock Related To Early Exercised Stock Options
ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions
36000
CY2019 pcvx Proceeds From Issuance Of Common Stock Related To Early Exercised Stock Options
ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions
120000
CY2018 pcvx Proceeds From Issuance Of Common Stock Related To Early Exercised Stock Options
ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions
123000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
374000
CY2019 pcvx Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
1097000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
374870000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41567000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62190000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-341000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
327224000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7114000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
29951000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58976000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66090000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36139000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
386200000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58976000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66090000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
7000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
40000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
75000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
494000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
21000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3000
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
270190000
CY2020 pcvx Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
134000
CY2019 pcvx Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
33000
CY2020Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-1.6870
CY2020Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
264000000.0
CY2020Q2 pcvx Payments Of Underwriting Discounts And Commissions
PaymentsOfUnderwritingDiscountsAndCommissions
20100000
CY2020Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3400000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:10.46%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those related to stock-based compensation expense, accruals for certain research and development costs, the valuation of deferred tax assets and income taxes. Management bases our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates. </p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:10.46%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject us to a concentration of credit risk consist primarily of cash and cash equivalents. We invested in money market funds as of December 31, 2020. We maintain bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and cash equivalents. We have not experienced any losses on our deposits of cash and cash equivalents.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:10.46%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to supplier concentration risk from our suppliers. We source our critical raw materials from a sole source supplier, Sutro Biopharma, Inc. (“Sutro Biopharma”). We also use one contract manufacturing organization (“CMO”), Lonza Ltd. (“Lonza”), to handle most of our manufacturing activities. If we were to experience disruptions in raw materials supplied by Sutro Biopharma, or in manufacturing activities at Lonza, we may experience significant delays in our product development timelines and may incur substantial costs to secure alternative sources of raw materials or manufacturing.  </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:10.46%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future results of operations involve a number of other risks and uncertainties. Factors that could affect our future operating results and cause actual results to vary materially from expectations include, but are not limited to: our early stages of clinical vaccine development; our ability to advance vaccine candidates into, and successfully complete, clinical trials on the timelines we project; our ability to adequately demonstrate sufficient safety and efficacy of our vaccine candidates; our ability to enroll subjects in our ongoing and future clinical trials; our ability to successfully manufacture and supply our vaccine candidates for clinical trials; our ability to obtain additional capital to finance our operations; our ability to obtain, maintain and protect our intellectual property rights; developments relating to our competitors and our industry, including competing vaccine candidates; general and market conditions; and other risks and uncertainties, including those more fully described in the “Risk Factors” section of this Annual Report on Form 10-K.</p>
CY2020 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 us-gaap Asset Impairment Charges
AssetImpairmentCharges
300000
CY2019 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2018 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2018Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2018Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7369000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6373000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4097000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2982000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3272000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3391000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1400000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1200000
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1000000.0
CY2020 us-gaap Capital Leases Income Statement Amortization Expense
CapitalLeasesIncomeStatementAmortizationExpense
0
CY2019 us-gaap Capital Leases Income Statement Amortization Expense
CapitalLeasesIncomeStatementAmortizationExpense
200000
CY2018 us-gaap Capital Leases Income Statement Amortization Expense
CapitalLeasesIncomeStatementAmortizationExpense
300000
CY2020Q4 pcvx Accrued Preclinical Studies Current
AccruedPreclinicalStudiesCurrent
2844000
CY2019Q4 pcvx Accrued Preclinical Studies Current
AccruedPreclinicalStudiesCurrent
844000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
490000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
397000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
432000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
64000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3766000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1305000
CY2020Q4 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P36M
CY2020 pcvx Percentage Of Annual Rental Payments Including Guaranteed Residual Value
PercentageOfAnnualRentalPaymentsIncludingGuaranteedResidualValue
0.90
CY2019Q4 pcvx Number Of Lab Equipment
NumberOfLabEquipment
2
CY2020Q1 pcvx Number Of Lab Equipment
NumberOfLabEquipment
2
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0
CY2020Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
0
CY2020 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
In July 2016, we entered into a five-year lease agreement for our headquarters facility located in Foster City, California (the “Headquarter Facility”). The original term of the lease was from September 1, 2016 to August 31, 2021, with two 30-month renewal options.
CY2020Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P30M
CY2020Q4 pcvx Lessee Operating Lease Extended Lease Term
LesseeOperatingLeaseExtendedLeaseTerm
P6M
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
742000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
190000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
932000
CY2020 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2019 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
600000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.25
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
35962362
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
20390095
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
160310000
CY2019Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
172037000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
52000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51071593
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51071593
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4059909
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4059909
CY2020 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
66982
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
91133
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2020Q4 pcvx Early Exercised Stock Options
EarlyExercisedStockOptions
15056
CY2019Q4 pcvx Early Exercised Stock Options
EarlyExercisedStockOptions
86409
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.38
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
66982
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
358264
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
302512
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
86163
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.88
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.46
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.48
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.62
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.52
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
19500000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-89217000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50274000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29485000
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29545810
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3795090
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3629896
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.02
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-13.25
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.12
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5188531
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.006
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.005
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.006
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.008
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.004
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.005
CY2020 pcvx Effective Income Tax Rate Reconciliation Change In Fair Value Of Tranche Liability
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability
0.000
CY2019 pcvx Effective Income Tax Rate Reconciliation Change In Fair Value Of Tranche Liability
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability
0.013
CY2018 pcvx Effective Income Tax Rate Reconciliation Change In Fair Value Of Tranche Liability
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability
0.038
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.003
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.004
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.007
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.221
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.218
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23845796
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19825674
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.242
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
52330000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25582000
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
528000
CY2019Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
379000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
2786000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
467000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1222000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
872000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
3381000
CY2020Q4 pcvx Deferred Tax Assets Tax Accrued Manufacturing Expenses
DeferredTaxAssetsTaxAccruedManufacturingExpenses
3374000
CY2019Q4 pcvx Deferred Tax Assets Tax Accrued Manufacturing Expenses
DeferredTaxAssetsTaxAccruedManufacturingExpenses
871000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
63621000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
28171000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
63621000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28171000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
400000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
300000
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2019 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
271000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
408000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
119000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
287000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
217000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
228000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
393000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
271000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
408000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24315000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18178000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16410000
CY2020Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14661000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3281000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
165000
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
354000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
61000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3046000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4898000
CY2020Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4792000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
27596000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
21224000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
21308000
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
19453000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-27596000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21224000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21308000
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-19453000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
454000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
904000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
290000
CY2020Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1284000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-27142000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-20320000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21018000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-20737000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.70
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.72
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4049848
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11803778
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
50895358
CY2020Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
50964294
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12628000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9968000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9630000
CY2019Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13381000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1316000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2264000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2510000
CY2019Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2456000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
13944000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
12232000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
12140000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
15837000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-15837000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
273000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1567000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13944000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12232000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12140000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
823000
CY2019Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1216000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-13671000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-10665000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-11317000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-14621000
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3671102
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3682897
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.72
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.90
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.93
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.69
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3857298
CY2019Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3965166

Files In Submission

Name View Source Status
0001564590-21-016110-index-headers.html Edgar Link pending
0001564590-21-016110-index.html Edgar Link pending
0001564590-21-016110.txt Edgar Link pending
0001564590-21-016110-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gk244c5yf1gl000001.jpg Edgar Link pending
gk244c5yf1gl000002.jpg Edgar Link pending
gk244c5yf1gl000003.jpg Edgar Link pending
gk244c5yf1gl000004.jpg Edgar Link pending
gk244c5yf1gl000005.jpg Edgar Link pending
gk244c5yf1gl000006.jpg Edgar Link pending
gk244c5yf1gl000007.jpg Edgar Link pending
gk244c5yf1gl000008.jpg Edgar Link pending
gk244c5yf1gl000009.jpg Edgar Link pending
gk244c5yf1gl000010.jpg Edgar Link pending
gk244c5yf1gl000011.jpg Edgar Link pending
gk244c5yf1gl000012.jpg Edgar Link pending
gk244c5yf1gl000013.jpg Edgar Link pending
gk244c5yf1gl000014.jpg Edgar Link pending
gk244c5yf1gl000015.jpg Edgar Link pending
gk244c5yf1gl000016.jpg Edgar Link pending
gk244c5yf1gl000017.jpg Edgar Link pending
gk244c5yf1gl000018.jpg Edgar Link pending
gk244c5yf1gl000019.jpg Edgar Link pending
gk244c5yf1gl000020.jpg Edgar Link pending
gk244c5yf1gl000021.jpg Edgar Link pending
gk244c5yf1gl000022.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pcvx-10k_20201231.htm Edgar Link pending
pcvx-10k_20201231_htm.xml Edgar Link completed
pcvx-20201231.xsd Edgar Link pending
pcvx-20201231_cal.xml Edgar Link unprocessable
pcvx-20201231_def.xml Edgar Link unprocessable
pcvx-20201231_lab.xml Edgar Link unprocessable
pcvx-20201231_pre.xml Edgar Link unprocessable
pcvx-ex231_853.htm Edgar Link pending
pcvx-ex311_9.htm Edgar Link pending
pcvx-ex312_8.htm Edgar Link pending
pcvx-ex321_7.htm Edgar Link pending
pcvx-ex322_6.htm Edgar Link pending
pcvx-ex42_374.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending